/
The Company Accuray Incorporated is a radiation therapy company that develops, manufactures, sells and supports market-changing solutions that are designed to deliver radiation treatments for even the most complex cases, while making commonly treatable cases even more straightforward, to meet the full spectrum of patient needs. We believe in comparison to conventional linear accelerators, our t…
$0.26
$0.01 (-3.70%)
EOD Jul 17, 2026
11.15% operating margin is respectable but not wide. ROIC at 18.14%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue growth slowed to 2.6%, essentially flat. This is a business that needs a catalyst.
Negative free cash flow of -$1M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$428M
▲ +2.6% YoY
Net Income (TTM)
-$46M
▲ +89.8% YoY
Op. Margin
3.64%
▲ +11.0pp YoY
ROIC
5.38%
▲ +18.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$26M
▲ +90.9% YoY
Op. Cash Flow (TTM)
-$19M
▲ +124.0% YoY
Net Debt
$144M
Cash & Equiv.
$38M
5Y CAGR: +3.7%
Continue Research
Accuray (ARAY)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Accuray scores 14/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Accuray scores 14 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 3.6% operating margin and a 5.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh ARAY's valuation and scores 14/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.